How to Cite
Abstract
Aim. Study of the possibilities of using quantitative parameters of single-photon emission computed tomography (SPECT) with [99mTс]-MIBI as predictors of the effectiveness of neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC).
Materials and methods. The study included 47 patients with ВС T1-4N0-3M0 stages. SPECT was performed before and after the 2nd course of NAC, a scintigraphic study was performed 20 minutes and 2 hours after the administration of [99mTс]-MIBI with the calculation of the tumor/background accumulation coefficient (TB) and the retention index (IR).
Results. When comparing quantitative parameters between groups of patients with stabilization, partial regression of the tumor and complete regression, no statistically significant relationships were noted. Subsequently, the patients were divided into groups with no tumor response to therapy and with an objective tumor response (partial and complete tumor regression). IR demonstrated a statistically significant difference in these groups - a lower indicator was observed in patients with an objective response to the treatment. ROC-analysis was used to assess the threshold values in predicting response to therapy, which demonstrates that IR is a predictor of moderate strength and, at a value less than 0.175, predicts an objective response to NAC with a sensitivity of 75% and a specificity of 60%.
Conclusion. The use of SPECT with [99mTc]-MIBI at the stages of preoperative treatment can provide not only a quick assessment of the response, but also be an early indicator of therapy resistance. Retention index values less than 0.175 predict an objective response to NAC with a sensitivity of 75% and a specificity of 60%.
References
Cain H, Macpherson IR, Beresford M, Pinder SE, Pong J, Dixon JM. Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice // Clin Oncol (R Coll Radiol). 2017, Oct;29(10): 642–652. doi: 10.1016/j.clon.2017.06.003.
Shien T., Iwata H. Adjuvant and neoadjuvant therapy for breast cancer // Jpn J Clin Oncol. 2020, Mar;9;50(3): 225–229.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis // Lancet. 2014; 384: 164–172. doi: 10.1016/S0140-6736(13)62422-8.
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes // J Clin Oncol. 2012; 30: 1796–1804. doi: 10.1200/JCO.2011.38.8595
van la Parra R.F., Kuerer H.M. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials // Breast Cancer Res. 2016;18(1)6: 28. doi:10.1186/s13058-016-0684-6.
Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V. Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy // Ann Surg. 2018 Dec;268(6):e61-e62. doi: 10.1097/SLA.0000000000002573.
Avril S, Muzic RF Jr, Plecha D, Traughber BJ, Vinayak S, Avril N. 18F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer // J Nucl Med. 2016, Feb;57(1): 34S-9S. doi: 10.2967/jnumed.115.157875.
Elvas F, Boddaert J, Vangestel C, Pak K, Gray B, Kumar-Singh S, Staelens S, Stroobants S, Wyffels L. (99m)Tc-Duramycin SPECT Imaging of Early Tumor Response to Targeted Therapy: A Comparison with (18)F-FDG PET // J Nucl Med. 2017, Apr;58(4):665–670. doi: 10.2967/jnumed.116.182014.
Heskamp S, Heijmen L, Gerrits D, Molkenboer-Kuenen JDM, Ter Voert EGW, Heinzmann K, Honess DJ, Smith DM, Griffiths JR, Doblas S, Sinkus R, Laverman P, Oyen WJG, Heerschap A, Boerman OC. Response Monitoring with [(18)F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases // Mol Imaging Biol. 2017, Aug; 19(4):540–549. doi: 10.1007/s11307-016-1021-2.
Kolinger GD, Vállez García D, Kramer GM, Frings V, Smit EF, de Langen AJ, Dierckx RAJO, Hoekstra OS, Boellaard R. Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients // EJNMMI Res. 2019, Feb;7;9(1):14. doi: 10.1186/s13550-019-0481-1.
Moo TA, Sanford R, Dang C, Morrow M. Overview of Breast Cancer Therapy // PET Clin. 2018, Jul;13(3):339–354. doi: 10.1016/j.cpet.2018.02.006.
Чернов В.И., Дудникова Е.А., Гольдберг В.Е., Кравчук Т.Л., Данилова А.В., Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Попова Н.О., Гольдберг А.В. Позитронная эмиссионная томография в диагностике и мониторинге лимфопролиферативных заболеваний // Медицинская радиология и радиационная безопасность. 2018; 63(6):41-50. [Chernov V.I., Dudnikova E.A., Goldberg V.E., Kravchuk T.L., Danilova A.V., Zelchan R.V., Medvedeva A.A., Sinilkin I.G., Bragina O.D. Popova N.O., Goldberg A.V. Positron emission tomography in the diagnosis and monitoring of lymphomas. Medicinskaya radiologiya i radiacionnaya bezopasnost'. 2018; 63(6): 41-50. (In Russ)] DOI: 10.12737/article_5c0b8d72a8bb98.40545646
Schmitz AMT, Teixeira SC, Pengel KE, Loo CE, Vogel WV, Wesseling J, Rutgers EJT, Valdés Olmos RA, Sonke GS, Rodenhuis S, Vrancken Peeters MJTFD, Gilhuijs KGA. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes // PLoS One. 2017, May;22;12(5):e0176782. doi: 10.1371/journal.pone.0176782
Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, Espié M, Hindié E. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer // Eur J Nucl Med Mol Imaging. 2015; 42:377–385. doi: 10.1007/s00259-014-2941-1.
Чанчикова Н.Г., Карлова Е.А., Савельева А.С., Силкина О.А., Чернов В.И., Зельчан Р.В., Синилкин И.Г., Брагина О.Д., Медведева А.А. Роль позитронно-эмиссионной томографии в прогнозировании раннего ответа опухоли на неоадъювантную химиотерапию рака молочной железы // Опухоли женской репродуктивной системы. 2020; 16(3):18-24. [Chanchikova N.G., Karlova E.A., Savel'eva A.S., Silkina O.A., Chernov V.I., Zeltchan R.V., Sinilkin I.G., Bragina O.D., Medvedeva A.A. Positron emission tomography for detection of distant metastases in patients with breast cancer. Sibirskij onkologicheskij zhurnal. 2020;16(3):18-24. (In Russ)] DOI: 10.17650/1994-4098-2020-16-3-18-24
Humbert O, Lasserre M, Bertaut A, Fumoleau P, Coutant C, Brunotte F, Cochet A. Breast Cancer Blood Flow and Metabolism on Dual-Acquisition (18)F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response // J Nucl Med. 2018, Jul; 59(7):1035–1041. doi: 10.2967/jnumed.117.203075.
Boughdad S, Champion L, Becette V, Cherel P, Fourme E, Lemonnier J, Lerebours F, Alberini JL. Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response // Cancer Imaging. 2020 Jan 28;20(1):11. doi: 10.1186/s40644-020-0287-4.
Канаев С.В., Новиков С.Н., Криворотько П.В., Семиглазова Т.Ю., Черная А.В., Туркевич Е.А., Брянцева Ж.В., Крживицкий П.И., Труфанова Е.С., Петрова А.С. Клиническое значение результатов маммосцинтиграфии у больных раком молочной железы, получающих неоадъювантную полихимиотерапию // Вопросы онкологии. 2016; 62(4): 479–484. [Kanaev S.V., Novikov S.N., Krivorotko P.V., Semiglazova T. Yu., Chernaya A.V., Turkevich E.A., Bryantseva Zh. V., Krzhivitsky P.I., Trufanova E.S., Petrova A.S. Clinical significance of mammoscintigraphy results in breast cancer patients receiving neoadjuvant polychemotherapy. Voprosy onkologii. 2016; 62(4): 479–484 (In Russ)]
Collarino A, de Koster EJ, Valdés Olmos RA, de Geus-Oei LF, Pereira Arias-Bouda LM. Is Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings // Clin Breast Cancer. 2018, Feb;18(1): 9–18. doi: 10.1016/j.clbc.2017.06.008.
Тицкая А.А., Чернов В.И., Слонимская Е.М., Синилкин И.Г., Зельчан Р.В. Маммосцинтиграфия с 99mTс-МИБИ в диагностике рака молочной железы // Сибирский медицинский журнал (г. Томск). [Titskaya A.A., Chernov V.I., Slonimskaya E.M., Sinilkin I.G., Zeltchan R.V. 99mT-MIBI mammoscintigraphy in breast cancer diagnosis. Sibirskij medicinskij zhurnal. 2010;25(4-1): 92-95 (In Russ)]
Guo C, Zhang C, Liu J, Tong L, Huang G. Is Tc-99m sestamibi scintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis // Nucl Med Commun. 2016, Jul;37(7): 675-88. doi: 10.1097/MNM.0000000000000502.
Mubashar M, Harrington KJ, Chaudhary KS, Lalani el-N, Stamp GW, Peters AM. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines // Acta Oncol. 2004;43:443-52. doi: 10.1080/02841860410031048.
Lee HS, Ko BS, Ahn SH, Son BH, Lee JW, Kim HJ, Yu JH, Kim SB, Jung KH, Ahn JH, Cha JH, Kim HH, Lee HJ, Song IH, Gong G, Park SH, Lee JJ, Moon DH. Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients // Breast Cancer Res Treat. 2014;145:91–100. doi: 10.1007/s10549-014-2920-z.
Novikov SN, Kanaev SV, Petr KV, Tatyana SY, Elena TA, Ludmila JA, Nikolay ID, Zhanna BV, Pavel KI. Technetium-99m methoxyisobutylisonitrile scintimammography for monitoring and early prediction of breast cencer response to neoadjuvant chemotherapy // Nucl Med Commun. 2015;36:795–801. doi: 10.1097/MNM.0000000000000331.
Novikov SN, Chernaya AV, Krzhivitsky PI, Kanaev SV, Krivorotko PV, Artemyeva AS, Popova NS. (99m)Tc-MIBI scintimammography and digital mammography in the diagnosis of multicentric breast cancer // Hell J Nucl Med. 2019, Sep-Dec;22(3): 172–178. doi: 10.1967/s002449911052.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2022